Awak raises $20m series B for on-the-go kidney dialysis machines

The Awak Singapore team / Photo credit: Awak

Kidney diseases have been called a “hidden epidemic” by some, with the chronic type affecting over 10% of the world’s global population. Dialysis, a procedure patients go through roughly three times a week, is also a hassle – the process can take three to five hours, not including travel time to hospitals.

That might change due to a wearable device that Singapore-based Awak Technologies is developing. Specifically designed for end-stage renal disease (ESRD) patients, this solution allows kidney dialysis to be performed on the go.

The medtech firm said it has raised over US$20 million in series B funding to complete the ongoing human pre-pivotal clinical trial with Singapore General Hospital and make essential enhancements to its flagship device, which Awak aims to launch in the US.

Funding details

• Funding amount: US$20,000,000
• Lead investors: Lion X Ventures, Vickers Venture Partners
• Other investors: Advanced MedTech, Eckuity Capital
• Stage: Series B
• Source

Awak Technologies was founded in 2007. Its main offering, called Awak PD, is a peritoneal dialysis (PD) system that aims to help reduce the need for long hours of in-center dialysis for ESRD patients.

Awak said it’s expected to start a final pivotal trial in the US in 2025. It also looks to develop new products and digital solutions to complement its PD device.

“A strong pipeline of relentless innovation at Awak in sorbent-based regeneration technology, remote patient monitoring, and AI will continue to transform the industry for better and for good, promoting kidney care decentralization and benefiting millions suffering,” said Irene Guo, co-CEO of Lion X Ventures – which co-led the round.

More details